



AGENDA

** Mountain Standard Time **

THURSDAY, JANUARY 9, 2025

6:00pm–8:00pm **Course Directors' Reception**

FRIDAY, JANUARY 10, 2025

6:45am–7:30am **Breakfast—Exhibit Hall/Poster Viewing**

7:30am–7:35am **Opening Remarks**
Presenter: Vlad Ratziu, MD, PhD

7:35am–8:05am **The Year 2024 in Review**
Presenter: Michael Charlton, MD, MBBS, FRCP

8:05am–8:15am **A Tribute to Stephen A. Harrison**
Presenter: Mary Rinella, MD

8:15am–10:05am **SESSION 1: In-depth Expert Analysis of MASH Clinical Trials - 2024**
Moderators: Rohit Loomba, MD, MHSc and Mary Rinella, MD

8:15am–8:30am **Tirzepatide Phase 2b**
Presenter: Prof. Quentin Anstee, FRCP

8:30am–8:45am **Semaglutide Primary Analysis Phase 3**
Presenter: Brent Tetri, MD

8:45am–9:00am **REGENERATE Long Term Outcome Data**
Presenter: Naga Chalasani, MD

9:00am–9:15am **Survodutide Phase 2b**
Presenter: Rohit Loomba, MD, MHSc

9:15am–9:30am **Emerging data in FGF-21 analogs**
Presenter: Mary Rinella, MD

9:30am–9:45am **Panel Discussion**



9:45am–10:05am **Break—Exhibit Hall/Poster Viewing – For Discussions & Networking**

10:05am–11:45am **SESSION 2: Deep Dive into Incretin and Endocrine-based Therapies**
Moderators: Manal Abdelmalek, MD, MPH, FACP, FACG, FAASLD and Vlad Ratziu, MD, PhD

10:05am–10:25am **Pleiotropic effects of FGF-21 in liver, brain and adipose tissue**
Presenter: Dr. Tim Rolph, D. Phil

10:25am–10:45am **Incretins Mono and Pluri Agonists Which Ones Make Most Sense?**
Presenter: Rohit Loomba, MD, MHSc

10:45am–11:05am **GLP1 Agonists and PAN-PPAR-Agonists; Extrahepatic Benefits and Risks**
Presenter: Samuel Klein, MD

11:05am–11:25am **Panel Discussion**

11:25am–11:35am **Belapectin administered at 2mg/kg/LBW for 18 months reduced the incidence of varices development in patients with MASH cirrhosis and portal hypertension: Top line results from the NAVIGATE trial**
Presenter: Naim Alkhouri, MD, FAASLD, DABOM

11:35am–11:45am **Liquid biopsy using whole genome methylation cell-free DNA signature for non-invasive diagnosis of at-risk MASH**
Presenter: Manal Abdelmalek, MD, MPH, FACP, FACG, FAASLD

12:00pm–1:00pm **Novo Nordisk CME Symposium: Comprehensive Case Challenges in MASH: Diagnosing, Staging, and Treating Patients in an Advancing Field**

4:00pm–5:50pm **SESSION 3: Refining Clinical Benefit in Outcome Trials: Can CSPH Save Cirrhosis Trials?**
Moderators: Meena Bansal MD and Naim Alkhouri, MD, FAASLD, DABOM

4:00pm–4:20pm **What Is CSPH and How Does It Change Prognosis?**
Presenter: Guadalupe Garcia-Tsao, MD

4:20pm–4:40pm **Non-Invasive Measurement of CSPH -Ready for Trial Time?**
Presenter: Juan Abraldes, MD, FRCPC

4:40pm–5:00pm **How to Exclude Cirrhosis in Candidates for MASH Therapy with Resmetirom and MASH Trials**
Presenter: Mazen Nouredin, MD, MHSc



5:00pm–5:30pm **Panel Discussion**

5:30pm–5:50pm **Break—Exhibit Hall/Poster Viewing – For Discussions & Networking**

5:50pm–7:00pm **SESSION 4: The Promise of New Pharmacological Agents + Pathophysiology**
Moderators: Michael Charlton, MD, MBBS, FRCP, Rohit Loomba, MD, MHSc and Vlad Ratzu, MD, PhD

5:50pm–6:00pm **HSD17B13**
Presenter: Nikhil Vergis, PhD

6:00pm–6:10pm **PNPLA3**
Presenter: Prof. Stefano Romeo, MD

6:10pm–6:20pm **FASN Inhibitors**
Presenter: Marie O'Farrell, PhD

6:20pm–6:30pm **GM-60106: A 5HT2A Antagonist for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH)**
Presenter: Prof. Hail Kim, MD

6:30pm–6:45pm **State of the art: "Differential mechanisms in early vs late hepatic fibrosis and prospects for cirrhosis reversal"**
Presenter: Scott Friedman, MD

6:45pm–7:00pm **Top 5 Basic Science Papers in MASH**
Presenter: Meena Bansal, MD



SATURDAY, JANUARY 11, 2025

6:45am–8:00am **Breakfast—Exhibit Hall/Poster Viewing**

8:00am–9:40am **SESSION 5: Can Digital Pathology Save MASH Trials**
Moderators: Prof. Quentin Anstee, FRCP and Dean Tai, PhD

8:00am–8:20am **Recent Progress in Identifying Ballooned Cells and Resolution of Steatohepatitis with AI Assisted DP**
Presenter: Prof. Quentin Anstee, FRCP

8:20am–8:40am **Recent Progress in Measuring Antifibrotic Effects: Data from Clinical Trials I. (Histoindex and Clinician)**
Presenters: Dean Tai, PhD and Mary Rinella, MD

8:40am–9:00am **Recent Progress in Measuring Antifibrotic Effects: Data from Clinical Trials II. (Pharmanest and Clinician)**
Presenters: Vlad Ratzu, MD, PhD and Mathieu Petitjean, PhD

9:00am–9:20am **AIM Explore: Assisting the Trials Vs Assisting the Clinician**
Presenters: Naim Alkhouri, MD, FAASLD, DABOM and Andy Beck, MD, PhD

9:20am–9:40am **Panel Discussion: Digital Pathology in Clinical Trials How Long Before Regulatory Qualification?**
Panelists: Cynthia Behling, MD, PhD, Prof. Quentin Anstee, FRCP, Dean Tai, PhD

9:40am–10:00am **Break—Exhibit Hall/Poster Viewing – For Discussions & Networking**

10:00am–12:00pm **SESSION 6: The Case for MetALD**
Moderators: Naga P. Chalasani, MD and Becky Taub, MD

10:00am–10:20am **Monitoring Alcohol Consumption in Clinical Trials: How and Why?**
Presenter: Rohit Loomba, MD, MHSc

10:20am–10:40am **Is MetALD An Impostor or A Distinct Entity?**
Presenter: J P Arab, MD, FRCPC

10:40am–11:00am **The Case for MetALD Trials and How to Conduct Them**
Presenter: Vijay Shah, MD

11:00am–11:20am **Alcohol Use Disorder and How It May Interfere with MetALD Trials**
Presenter: Brian Lee, MD

January 9-11, 2025 ~ The Chateaux Deer Valley

7815 Royal Street East, Park City, Utah



11:20am–11:45am **Panel Discussion**

12:15pm–1:15pm **Madrigal CME Symposium: Treating At-Risk MASH: What Are You Waiting For?**

4:00pm–5:10pm **SESSION 7: Case Based Patient Journey**

Moderators: Alina Allen, MD, MS and Vlad Ratziu, MD, PhD

4:00pm–4:30pm **Case Based Patient Journey**

Presenter: Mary Rinella, MD

Panelists: George Behrens, MD and Brent Tetri, MD

4:30pm–4:50pm **Novel Genetics Approaches to Risk Stratifications**

Presenter: Prof. Stefano Romeo, MD

4:50pm–5:00pm **First-in-human phase 1 study of the safety and pharmacodynamic effects of OA-235i, a PAR2 pepducin, in adults with metabolic dysfunction-associated steatotic liver disease (MASLD) and steatohepatitis (MASH)**

Presenter: Athan Kuliopulos, MD, PhD

5:00pm–5:10pm **Serum proteomics to unravel the role of insulin resistance in rare and common steatotic liver diseases**

Presenter: Yaron Rotman, MD, MSc

5:10pm–5:30pm **Break—Exhibit Hall/Poster Viewing – For Discussions & Networking**

5:30pm–7:10pm **SESSION 8: Surveying the Post Approval Landscape**

Moderators: Vijay Shah, MD, Michelle Long, MD, MSc, Michael Charlton, MD, MBBS, FRCP

5:30pm–5:50pm **New Data on NIT Surrogates for MASH Trials**

Presenter: Alina Allen, MD, MS

5:50pm–6:10pm **Future of Combination Therapies**

Presenter: Prof. Dr. Phil Newsome, FRCPE

6:10pm–6:30pm **How Did Clinical Practice Change with Resmetirom on the Market?**

Presenter: Manal Abdelmalek, MD, MPH, FACP, FACG, FAASLD

6:30pm–6:50pm **Opportunities for Drug Development in the Resmetirom Era**

Presenter: Vlad Ratziu, MD, PhD

6:50pm–7:10pm **Panel Discussion**

7:10pm **Wrap Up**

Presenter: Rohit Loomba, MD, MHSc

Meeting Adjournment